Navigation Links
Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 5, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) announced topline results of a six month U.S. Phase 3 study of Androxal(TM), an oral drug being developed to restore normal testicular function in men with secondary hypogonadism. Further, Androxal demonstrates non-inferiority in all the endpoints of the study, compared to Androgel(R), a cream which is the leading treatment for low testosterone.

Study Details and Results

This six month, double-blind study compared two doses of oral Androxal, 12.5mg and 25mg, to matching placebo capsules and open label Androgel at any dose to be used per manufacturer's instructions. The study's primary efficacy endpoint was the proportion of patients at month three who showed morning total serum testosterone concentrations within the normal physiological range (300 to 1040 ng/dl). This endpoint was also extended to include the outcome at month six as well as the assessment of non-inferiority to Androgel.

Of the 191 patients enrolled in the trial, 144 patients completed the study. There were 8 and 15 premature drop outs in the 12.5mg and 25mg Androxal arms, respectively, 15 drop outs in the placebo arm, and 13 drop outs in the Androgel arm. There were no drop outs due to an adverse event or lack of compliance in the Androxal treatment groups. The majority of the other drop outs were due to either withdrawal of consent or "lost to follow-up". There were 188 patients in the modified intent-to-treat group ("MITT") consisting of all randomized patients with at least one efficacy evaluation.

The proportion of men in the 12.5mg and 25mg treatment arms with total testosterone in the physiological range at month three using the last observation carried forward was 72.7% and 79.2%, respectively, and those on Androgel and placebo the proportion was 57.4% and 28.3%, respectively. These results confirm non-inferiority to Androge
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
7. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
8. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
9. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
10. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
11. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
Post Your Comments:
(Date:3/31/2015)... ROCHELLE, N.Y. , March 31, 2015 /PRNewswire-USNewswire/ ... it will be featured in the American Medical ... by ITN Productions. AMGA,s "High Performing ... on the challenges facing the nation,s healthcare system ... Medical Letter is profiled along with other leading ...
(Date:3/31/2015)... -- Accelerated orthodontic treatment will be a featured ... Annual Session, May 15-19, as seven of the ... ® . Manufactured by OrthoAccel ® Technologies, ... a FDA-cleared, Class II medical device that speeds ... percent with just 20 minutes of daily use. ...
(Date:3/31/2015)... DALLAS , March 31, 2015 ... H1 2015" therapeutic market research report of 68 ... its online business intelligence library. The ... information on the therapeutic development for Pemphigus ... therapeutics assessment by drug target, mechanism of action ...
Breaking Medicine Technology:AMGA's High Performing Health News Program Features The Medical Letter 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4
... GSK ) announced today that the U.S. Centers ... Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent ... girls and young women to protect against cervical pre-cancers ... 18. The ACIP specifically recommended CERVARIX for routine ...
... Accuray Incorporated (Nasdaq: ARAY ), a global ... to establish an America,s region thereby establishing regionalized management ... , The formation of this new Americas region, along ... Japan, gives each region control of revenue and profitability ...
Cached Medicine Technology:CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women 2CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women 3CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women 4Accuray Announces Regionalized Management Strategy for Americas 2Accuray Announces Regionalized Management Strategy for Americas 3
(Date:3/31/2015)... 2015 Bon Secours New York Health ... Schervier Nursing Care Center family last week. The Sisters ... in Yonkers which is scheduled to close later this ... of the Sisters of Charity of New York, the ... to place their Sisters at Schervier Nursing Care Center ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Cosmetic Town, ... the Internet, is proudly enduring adding news to its ... and the consumers of plastic surgery and cosmetic medicine ... user-friendly pages and interconnected sections, the Cosmetic Town community ... addition to the Cosmetic Town site navigation, News and ...
(Date:3/31/2015)... 31, 2015 Karen A. Daley, Ph.D. ... Rivier University’s Commencement ceremony on May 9, ... letters in recognition of her eminent career as a ... a front-line caregiver and senior staff nurse at Brigham ... advancing to leadership roles, including President of the American ...
(Date:3/31/2015)... Indosoft, developer of the Q-Suite call center software suite, announces ... 5.x line. The industry leading contact center ACD ... for more than a decade. By announcing an end of ... fully embrace newer Asterisk features and improve performance. , Q-Suite ... more than a decade. The use of Asterisk, a free, ...
(Date:3/31/2015)... Clinovo, a leading provider of cloud-based ... the premiere voice of Northern California’s Life Science ... , BayBio brings together the collective strength ... productive life science cluster, helping companies grow, connect ... pressing challenges. , “We are thrilled to ...
Breaking Medicine News(10 mins):Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2
... CryoCor, Inc. (Nasdaq:,CRYO), a medical device company focused on ... Brennan, President and Chief,Executive Officer, and Gregory J. Tibbitts, ... Group First Annual Growth Conference in,New York, NY on ... The Grand,Hyatt Hotel. A live Web cast and ...
... Sept. 17 John Brooke, General Manager of,Billian,s ... speaking at Dreamforce ,07 Global Gathering, Salesforce.com,s 5th,Annual ... week. Dreamforce is the ultimate gathering of ... base of Salesforce and AppExchance,users spanning industries, roles ...
... screening may only be modestly accurate, according to researchers from ... North Carolina. In a study that appears in the October ... the usefulness of a scale that asks patients in primary ... to 10 (worst pain). , Universal pain screening ...
... September ... 18th, NEW YORK, Sept. ... meet their millennium,commitment to halve hunger by 2015, the international development agency,ActionAid,s HungerFREE ... table" of the 62nd United Nations General Assembly,Meetings. "The UN is failing ...
... Contrary to concerns that restricting work hours for ... or the residents education, a study in the September ... Surgeons found that limiting work hours does not compromise ... study found that the new model improved overall teaching ...
... ROSEVILLE, Calif., Sept. 17 S.M.A.R.T. Association,Inc. ("SMART"), ... Council,Member" of the Smart Card Alliance, a not-for-profit, ... and,widespread application of Smart Card technology. The ... for smart card,technology, leading industry discussions on the ...
Cached Medicine News:Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:Billian's HealthDATA GM Speaking on Dreamforce 07 Panel 2Health News:Rating your pain from 0 to 10 might not help your doctor 2Health News:HungerFREE Campaign Tells UN: 'Put food on the table' 2Health News:Study finds limiting work hours for surgical residents enhances training 2Health News:SMART Association Becomes 'Healthcare Council Member' of Smart Card Alliance 2
For primary and revision cases...
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Implex cemented hip stem....
Medicine Products: